Qiwen Zhong

Dec 3, 2024 | law360.co.uk | Lisa Silverman |Qiwen Zhong

ADVERTISEMENT Don't want ads? Subscribe or login now. By Lisa Silverman and Qiwen Zhong ( December 3, 2024, 10:13 AM EST) -- A recent decision by the Patent Trial and Appeal Board sheds light on certain pitfalls patent applicants may encounter when submitting declarations under Title 37 of the Code of Federal Regulations, Section 1.132....

Dec 3, 2024 | law360.co.uk | Lisa Silverman |Qiwen Zhong

ADVERTISEMENT Don't want ads? Subscribe or login now. By Lisa Silverman and Qiwen Zhong ( December 3, 2024, 10:13 AM EST) -- A recent decision by the Patent Trial and Appeal Board sheds light on certain pitfalls patent applicants may encounter when submitting declarations under Title 37 of the Code of Federal Regulations, Section 1.132....

Oct 29, 2024 | jdsupra.com | Lisa Silverman |Qiwen Zhong

A recent decision by the Patent Trial and Appeal Board (PTAB) sheds light on certain pitfalls patent applicants may encounter when submitting declarations under 37 C.F.R. § 1.132 (“Rule 132 Declarations”). Rule 132 Declarations are frequently used in life sciences patent prosecution to submit data in support of a patent application. They are an important tool for rebutting obviousness rejections raised under 35 U.S.C. § 103 by establishing that an applicant’s invention produces unexpected results.

Oct 29, 2024 | jdsupra.com | Lisa Silverman |Qiwen Zhong

A recent decision by the Patent Trial and Appeal Board (PTAB) sheds light on certain pitfalls patent applicants may encounter when submitting declarations under 37 C.F.R. § 1.132 (“Rule 132 Declarations”). Rule 132 Declarations are frequently used in life sciences patent prosecution to submit data in support of a patent application. They are an important tool for rebutting obviousness rejections raised under 35 U.S.C. § 103 by establishing that an applicant’s invention produces unexpected results.

Nov 13, 2023 | lexology.com | Lisa Silverman |Brigid DeCoursey Bondoc |David Shaw |Qiwen Zhong

In the latest attempt to promote generic drug competition and reduce drug prices, and consistent with broader efforts to enforce the antitrust laws more aggressively, the Federal Trade Commission (FTC) announced on November 7, 2023, challenges to more than 100 patent listings by brand drug manufacturers in the Food and Drug Administration’s (FDA) Orange Book. The challenges implicate 62 unique patents and 18 FDA approved products.